112 related articles for article (PubMed ID: 11858821)
1. Evidences of conformational changes in class II Major Histocompatibility Complex molecules that affect the immunogenicity.
Neveu R; Auriault C; Angyalosi G; Georges B
Mol Immunol; 2002 Feb; 38(9):661-7. PubMed ID: 11858821
[TBL] [Abstract][Full Text] [Related]
2. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens.
Zhu X; Bavari S; Ulrich R; Sadegh-Nasseri S; Ferrone S; McHugh L; Mage M
Eur J Immunol; 1997 Aug; 27(8):1933-41. PubMed ID: 9295029
[TBL] [Abstract][Full Text] [Related]
3. Structure of a complex of the human alpha/beta T cell receptor (TCR) HA1.7, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4 (DRA*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity.
Hennecke J; Wiley DC
J Exp Med; 2002 Mar; 195(5):571-81. PubMed ID: 11877480
[TBL] [Abstract][Full Text] [Related]
4. The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide binding.
Murthy VL; Stern LJ
Structure; 1997 Oct; 5(10):1385-96. PubMed ID: 9351812
[TBL] [Abstract][Full Text] [Related]
5. Disruption of hydrogen bonds between major histocompatibility complex class II and the peptide N-terminus is not sufficient to form a human leukocyte antigen-DM receptive state of major histocompatibility complex class II.
Schulze MS; Anders AK; Sethi DK; Call MJ
PLoS One; 2013; 8(7):e69228. PubMed ID: 23976922
[TBL] [Abstract][Full Text] [Related]
6. The MHC class II-associated invariant chain-derived peptide clip binds to the peptide-binding groove of class II molecules.
Wu S; Gorski J
Mol Immunol; 1996; 33(4-5):371-7. PubMed ID: 8676888
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies specific for the empty conformation of HLA-DR1 reveal aspects of the conformational change associated with peptide binding.
Carven GJ; Chitta S; Hilgert I; Rushe MM; Baggio RF; Palmer M; Arenas JE; Strominger JL; Horejsi V; Santambrogio L; Stern LJ
J Biol Chem; 2004 Apr; 279(16):16561-70. PubMed ID: 14757758
[TBL] [Abstract][Full Text] [Related]
8. Peptide linkage to the α-subunit of MHCII creates a stably inverted antigen presentation complex.
Schlundt A; Günther S; Sticht J; Wieczorek M; Roske Y; Heinemann U; Freund C
J Mol Biol; 2012 Oct; 423(3):294-302. PubMed ID: 22820093
[TBL] [Abstract][Full Text] [Related]
9. Structure of a covalently stabilized complex of a human alphabeta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1.
Hennecke J; Carfi A; Wiley DC
EMBO J; 2000 Nov; 19(21):5611-24. PubMed ID: 11060013
[TBL] [Abstract][Full Text] [Related]
10. Different regions of the N-terminal domains of HLA-DR1 influence recognition of individual peptide-DR1 complexes.
Tuosto L; Karr RW; Fu XT; Olson RR; Cundari E; Piccolella E; Lechler R; Lombardi G
Hum Immunol; 1994 Aug; 40(4):312-22. PubMed ID: 7528190
[TBL] [Abstract][Full Text] [Related]
11. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
Stumptner P; Benaroch P
EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
[TBL] [Abstract][Full Text] [Related]
12. Interactions among polymorphic and conserved residues in MHC class II proteins affect MHC-peptide conformation and T cell recognition.
Tate KM; Lee C; Edelman S; Carswell-Crumpton C; Liblau R; Jones PP
Int Immunol; 1995 May; 7(5):747-61. PubMed ID: 7547702
[TBL] [Abstract][Full Text] [Related]
13. A conformational change in the human major histocompatibility complex protein HLA-DR1 induced by peptide binding.
Zarutskie JA; Sato AK; Rushe MM; Chan IC; Lomakin A; Benedek GB; Stern LJ
Biochemistry; 1999 May; 38(18):5878-87. PubMed ID: 10231540
[TBL] [Abstract][Full Text] [Related]
14. The N-terminal region of photocleavable peptides that bind HLA-DR1 determines the kinetics of fragment release.
Negroni MP; Stern LJ
PLoS One; 2018; 13(7):e0199704. PubMed ID: 29965980
[TBL] [Abstract][Full Text] [Related]
15. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
Carstens C; Newman DK; Bohlen H; König A; Koch N
Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
[TBL] [Abstract][Full Text] [Related]
16. Sodium dodecyl sulfate stability of HLA-DR1 complexes correlates with burial of hydrophobic residues in pocket 1.
Natarajan SK; Stern LJ; Sadegh-Nasseri S
J Immunol; 1999 Mar; 162(6):3463-70. PubMed ID: 10092802
[TBL] [Abstract][Full Text] [Related]
17. Exploration of the P6/P7 region of the peptide-binding site of the human class II major histocompatability complex protein HLA-DR1.
Zavala-Ruiz Z; Sundberg EJ; Stone JD; DeOliveira DB; Chan IC; Svendsen J; Mariuzza RA; Stern LJ
J Biol Chem; 2003 Nov; 278(45):44904-12. PubMed ID: 12952957
[TBL] [Abstract][Full Text] [Related]
18. Invariant chain made in Escherichia coli has an exposed N-terminal segment that blocks antigen binding to HLA-DR1 and a trimeric C-terminal segment that binds empty HLA-DR1.
Park SJ; Sadegh-Nasseri S; Wiley DC
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):11289-93. PubMed ID: 7479981
[TBL] [Abstract][Full Text] [Related]
19. HLA-DO as the optimizer of epitope selection for MHC class II antigen presentation.
Poluektov YO; Kim A; Hartman IZ; Sadegh-Nasseri S
PLoS One; 2013; 8(8):e71228. PubMed ID: 23951115
[TBL] [Abstract][Full Text] [Related]
20. HLA-DR1 (DRB1*0101) and DR4 (DRB1*0401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen.
Rosloniec EF; Whittington KB; Zaller DM; Kang AH
J Immunol; 2002 Jan; 168(1):253-9. PubMed ID: 11751969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
